Changes in UCP2, PPARgamma2, and c/EBPalpha gene expression induced by a neuropeptide Y (NPY) related receptor

J Margareto1, I Rivero, A Monge

  • 1Department of Physiology and Nutrition, University of Navarra, Pamplona, Spain.

Insights

A novel Neuropeptide Y (NPY) antagonist, S.A.0204, reduced body fat and increased body temperature in animal models. This compound shows potential as an anti-obesity drug by impacting energy expenditure and fat deposition.

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Pharmacology

Background:

  • Neuropeptide Y (NPY) plays a role in regulating body fat by influencing appetite and fat breakdown.
  • Obesity management strategies are exploring new therapeutic targets, including NPY receptors.

Purpose of the Study:

  • To investigate the anti-obesity potential of a novel NPY receptor antagonist, S.A.0204.
  • To evaluate the effects of S.A.0204 on adipocyte lipid metabolism, thermogenesis, and fat deposition.

Main Methods:

  • Administration of S.A.0204 to animals on a high-energy diet.
  • Measurement of body fat weight, body temperature, and gene expression (UCP2, PPARy, CIEBPalpha) in white adipose tissue.

Main Results:

  • S.A.0204 administration decreased body fat weight and increased body temperature in animals on a high-energy diet.
  • Increased UCP2 mRNA expression in white adipose tissue correlated with elevated body temperature.
  • S.A.0204 prevented white adipose tissue growth by impairing PPARy and CIEBPalpha mRNA expression.

Conclusions:

  • The NPY antagonist S.A.0204 demonstrates potential for obesity management.
  • S.A.0204 may regulate body fat by influencing energy dissipation and white adipose tissue deposition.
  • This compound represents a promising pharmacological strategy for combating obesity.